Brenetafusp

根据各大药企在2024年的营收，行业媒体Fierce Pharma于近日公布了全球前20大药企排名。在这份名单中，强生（Johnson & Johnson）、罗氏（Roche）、默沙东（MSD）位居前三。本文将为各位读者朋友们整理这些药企在近期取得的进展。药明康德团队根据公开资料制图（在此排名中，排除各家公司在健康科学领域之外的收入，美元换算是基于年度平均汇率进行）强生2024年营收：888亿美元近期，强生公司取得了多项重要监管进展。今年3月，美国FDA批准了其抗IL-23抗体Tremfya用于治疗中度至重度活动性克罗恩病成人患者。根据新闻稿，Tremfya是首个同时提供皮下注射和静脉注射诱导治疗方案以治疗此类患者的IL-23抑制剂。此外，今年1月，强生的Spravato鼻喷雾剂获FDA批准，用于治疗难治性抑郁症（TRD）成人患者，成为首款获批作为单药疗法、用于对至少两种口服抗抑郁药应答不佳的成人重度抑郁症（MDD）患者的药物。在欧洲，强生也取得了重要突破。其双抗疗法Rybrevant联合Lazcluze获得欧盟委员会批准一线治疗携带EGFR第19号外显子缺失（ex19del）或第21号外显子L858R突变的晚期非小细胞肺癌（NSCLC）成年患者。罗氏2024年营收：653亿美元罗氏近年来通过产品创新和战略收购持续强化其治疗管线。其双特异性抗体Vabysmo在2022年获批后，又于2024年7月获FDA批准单剂量预填充注射器剂型，显著提升了用药便利性。在免疫疗法领域，罗氏2024年以15亿美元收购Poseida Therapeutics，获得其异体细胞疗法平台和基因编辑工具，为开发潜在"first-in-class"疗法奠定基础。同时，其双特异性抗体Columvi和Lunsumio分别在中美两国取得重要监管进展，前者联合吉西他滨和奥沙利铂用以治疗复发或难治性弥漫性大B细胞淋巴瘤（DLBCL）患者的补充生物制品许可申请（sBLA）已被美国FDA受理，有望在今年获批；后者已于2024年年末获得中国国家药监局（NMPA）批准上市，治疗复发或难治性滤泡性淋巴瘤（FL）成人患者。默沙东2024年营收：642亿美元默沙东公司正通过战略性收购和管线布局规划未来发展方向，其中代表性的交易包括：2021年以115亿美元收购Acceleron Pharma，获得肺动脉高压创新疗法sotatercept（该药物已于2023年3月获FDA批准，有望成为该领域的基石性疗法）；2023年以108亿美元收购Prometheus Biosciences，补充了溃疡性结肠炎、克罗恩病等自身免疫疾病管线；以及2023年达成的总额30亿美元的EyeBiotech收购协议，拓展眼科治疗领域。默沙东公司高管在近期电话会议中表示，公司正持续关注各类研发和商业合作机会，以确保持续的创新能力和造福患者。辉瑞2024年营收：636亿美元辉瑞在2024年持续推动新产品上市并加强战略布局。在肿瘤领域，BRAF抑制剂Braftovi组合治疗方案获FDA加速批准用于BRAF V600E突变转移性结直肠癌，成为该适应症首个获批的包含BRAF靶向疗法的组合疗法；血友病领域则取得双重突破，皮下注射疗法Hympavzi获FDA批准，一次性基因疗法Durveqtix获得欧盟有条件上市许可。辉瑞同时积极拓展研发合作网络：9月与Flagship Pioneering合作开展心血管和肾脏疾病领域研究项目；11月又与Flagship旗下公司合作开发肥胖症和NSCLC新靶向疗法；在自身免疫疾病领域，通过辉瑞Ignite与Acepodia合作开发创新细胞疗法。艾伯维2024年营收：563亿美元艾伯维成功构建了多元化产品矩阵：免疫学领域，IL-23抑制剂Skyrizi于2024年6月获批溃疡性结肠炎适应症，与JAK抑制剂Rinvoq形成炎症性肠病全谱系覆盖；肿瘤治疗取得突破性进展，抗体偶联药物（ADC）Elahere获美国FDA完全批准，与Genmab合作开发的Epkinly获得美国FDA加速批准，成为获FDA批准用以治疗复发或难治性滤泡性淋巴瘤成人患者的首个皮下注射T细胞接合双特异性抗体；抗感染领域方面，其与辉瑞合作开发的Emblaveo已获欧盟和美国FDA批准治疗多重耐药革兰氏阴性菌感染；该公司同时在神经退行性疾病管线新增帕金森病疗法Vyalev。为强化研发管线，艾伯维2024年开展了系列战略收购：收购Nimble Therapeutics获得口服肽类IL-23R抑制剂及肽类药物开发平台，整合Aliada Therapeutics的ALIA-1758布局阿尔茨海默病赛道，囊获Celsius Therapeutics的TREM1靶向抗体完善炎症性疾病矩阵，收购Landos Biopharma并获得其NLRX1激动剂强化炎症性肠病管线。通过"自主开发+战略收购"双重策略，艾伯维系统构建覆盖免疫、肿瘤、抗感染及神经退行性疾病的创新产品组合，为其可持续增长奠定基础。阿斯利康2024年营收：541亿美元2024年，阿斯利康在肿瘤和罕见病领域取得多项重要进展。其重磅EGFR抑制剂Tagrisso获得美国FDA两项新适应症批准：一是联合化疗治疗局部晚期或转移性EGFR突变NSCLC成人患者；二是用于治疗放化疗后不可切除的III期EGFR突变NSCLC患者。2025年1月，该公司与第一三共（Daiichi Sankyo）联合开发的ADC疗法Datroway获FDA批准上市，用于HR阳性/HER2阴性乳腺癌治疗；而口服补体因子D抑制剂Voydeya也于2024年4月获批，作为Ultomiris/Soliris的附加疗法用于阵发性睡眠性血红蛋白尿症（PNH）患者的血管外溶血管理。此外，阿斯利康2024年以20亿美元收购Fusion Pharmaceuticals，获得其靶向前列腺特异性膜抗原（PSMA）的锕系放射偶联药物；同年10月又以1亿美元预付款与石药集团达成针对脂蛋白（a）的临床前药物YS2302018的独家许可协议。随着这些战略布局的推进，2025年阿斯利康预计将迎来多个关键临床数据读出。诺华2024年营收：503亿美元2024年，诺华在肿瘤、肾病及放射性配体治疗领域取得多项突破性进展。其CDK4/6抑制剂Kisqali获美国FDA和欧盟委员会批准，联合芳香酶抑制剂用于HR阳性/HER2阴性早期乳腺癌（包括无淋巴结转移的患者）的辅助治疗；费城染色体阳性慢性髓系白血病治疗药物Scemblix则凭借优于标准疗法的3期数据获得FDA加速批准。在肾病领域，补体替代通路因子B抑制剂Fabhalta先后于2024年8月和3月获批治疗IgA肾病和C3肾小球病。此外，放射性配体疗法（RLT）Pluvicto也于2025年3月获FDA批准用于PSMA阳性转移性去势抵抗性前列腺癌（mCRPC）患者。通过战略性收购，诺华持续强化研发管线布局：2024年5月以超17亿美元收购Mariana Oncology拓展放射性配体疗法研发管线；11月以11亿美元收购Kate Therapeutics，布局基因治疗；同年还以29亿美元收购MorphoSys，增强血液肿瘤领域优势。百时美施贵宝2024年营收：483亿美元去年，百时美施贵宝的多款创新疗法获得监管突破与临床应用拓展。在血液肿瘤领域，公司3月获得CD19靶向CAR-T疗法Breyanzi加速批准，用于治疗复发/难治性慢性淋巴细胞白血病和小淋巴细胞淋巴瘤（SLL），并于5月扩展至滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）适应症；PD-1抑制剂Opdivo则在3月获批联合化疗用于尿路上皮癌一线治疗，10月进一步扩展至可切除NSCLC围手术期治疗，其皮下注射剂型Opdivo Qvantig更于年底获批，将给药时间缩短至5分钟。靶向BCMA的CAR-T疗法Abecma则于4月获批用于多发性骨髓瘤，在临床试验中，该疗法将无进展生存期提高至标准疗法的三倍以上；酪氨酸激酶抑制剂（TKI）Augtyro和KRAS G12C抑制剂Krazati分别在6月获加速批准用于实体瘤和结直肠癌治疗；神经精神领域则迎来突破——Cobenfy成为近十年来首个获批治疗精神分裂症的新机制药物。研发合作方面，公司通过战略合作强化管线布局：年初与VantAI合作开发分子胶新靶点，与Immunocore合作探索TCR双特异疗法IMC-F106C联合Opdivo治疗黑色素瘤的疗效和安全性；10月携手Prime Medicine开发下一代T细胞疗法；年底则与BioArcti达成全球许可协议，推进靶向焦谷氨酸修饰β淀粉样蛋白的抗体项目开发。礼来2024年营收：450亿美元2024年，礼来在多个疾病领域实现关键监管突破：5月，RET激酶抑制剂Retevmo获批用于治疗2岁及以上RET基因变异相关实体瘤及甲状腺癌患儿，成为首款覆盖12岁以下RET突变儿童的靶向疗法，6月，该药加速批准转为完全批准用于治疗RET融合阳性甲状腺癌全年龄段患者。7月，靶向β淀粉样蛋白的单抗Kisunla获批治疗早期阿尔茨海默病成人患者；9月，IL-13抑制剂Ebglyss获准用于治疗12岁以上、体重≥40公斤且局部治疗无效的中重度特应性皮炎患者；年底，重磅GLP-1/GIP受体双重激动剂Zepbound获批改善中重度阻塞性睡眠呼吸暂停肥胖患者的呼吸症状。在合作布局上，礼来通过多项战略合作强化管线：2024年初与Isomorphic Labs合作开发基于AlphaFold技术的小分子疗法；7月斥资32亿美元收购Morphic Holding，获得炎症性肠病口服整合素疗法MORF-057；9月与HAYA Therapeutics达成10亿美元的多年协议，利用其RNA引导基因调控平台开发代谢疾病疗法；10月扩展与KeyBioscience的合作，聚焦胰淀素/降钙素双重激动剂（DACRA）在肥胖及相关疾病中的应用。赛诺菲2024年营收：444.6亿美元2024年，赛诺菲与再生元共同开发的重磅抗炎药Dupixent斩获多项关键适应症：年初获FDA批准用于1-11岁嗜酸性粒细胞性食管炎（EoE）儿童患者；年中获美国FDA和欧洲药品管理局批准作为慢性阻塞性肺病（COPD）患者的附加维持治疗，并在随后获FDA批准作为慢性鼻窦炎伴鼻息肉（CRSwNP）青少年患者的辅助维持治疗。此外，IL-6拮抗剂Kevzara获批治疗活动性多关节型幼年特发性关节炎（pJIA）患者，抗CD38抗体Sarclisa则联合VRd方案成为不适合自体干细胞移植的新确诊多发性骨髓瘤成人患者的一线疗法。战略合作方面，赛诺菲1月以17亿美元收购Inhibrx，获得α-1抗胰蛋白酶缺乏症疗法INBRX-101；同月与Synthekine合作开发IL-10受体激动剂布局炎症性疾病；9月与RadioMedix和Orano Med达成3.2亿欧元独家许可协议，开发基于同位素铅的放射性配体疗法；10月追加3亿欧元股权投资，加速与Orano Med在罕见癌症及下一代RLT领域的合作。诺和诺德2024年营收：约421亿美元2024年，诺和诺德重磅产品Wegovy（semaglutide，司美格鲁肽）注射液斩获心血管保护新适应症，成为获FDA批准用于辅助患有心血管疾病及肥胖或超重的成年人预防重大心血管事件的首款减重药物。在2024年欧洲肥胖大会（ECO）上，该公司公布了Wegovy的长期减重效果数据，其疗效可维持长达4年。诺和诺德突破性皮下注射血友病疗法Alhemo获FDA批准，是针对伴抑制物血友病A或B患者的同类疗法中的首款皮下注射治疗方案。该公司还达成多项超5亿美元的研发合作，聚焦利用表观遗传调控开发肥胖管理潜在新疗法、针对代谢功能障碍相关脂肪性肝炎（MASH）的小分子药物、分子胶降解剂的开发，以及利用肝外脂质纳米颗粒（LNP）递送技术推进针对心脏代谢性疾病和罕见病的创新基因药物（genetic medicine）的开发。GSK2024年营收：约401亿美元GSK的PD-1抑制剂Jemperli在局部晚期错配修复缺陷（dMMR）/高微卫星不稳定性（MSI-H）直肠癌患者中展现出前所未有的疗效，并获得FDA授予的突破性疗法认定。近期，该公司的抗生素gepotidacin获FDA批准上市，是近30年来首个治疗单纯性尿路感染的新型口服抗生素。疫苗方面，GSK的带状疱疹疫苗Shingrix的长期随访数据显示，其对50岁以上成人的保护效力持续超10年。2024年，GSK达成了多项超5亿美元的收购和合作协议，覆盖呼吸道疾病、自身免疫疾病、肿瘤及疫苗领域，包括收购Aiolos Bio公司以获得用于治疗哮喘的胸腺基质淋巴细胞生成素（TSLP）靶向单抗AIO-001，收购用于治疗B细胞驱动的自身免疫疾病的T细胞接合器（TCE）CMG1A46，引进映恩生物（Duality Biologics）的抗癌抗体偶联药物DB-1324，以及深化用于治疗传染病的mRNA疫苗的开发合作。安进2024年营收：约334亿美元2024年6月，美国FDA批准安进双特异性抗体疗法Blincyto（blinatumomab），用于年龄一个月或以上、CD19阳性、费城染色体阴性B细胞前体急性淋巴细胞白血病（B-ALL）患者的巩固阶段治疗，无论患者的可测量残留病灶状态如何。在一项3期临床试验中，接受诱导后巩固治疗的B-ALL患者的5年总生存率超80%。近期，该公司的抗CD19抗体Uplizna获FDA批准扩展适应症，用于治疗免疫球蛋白G4相关疾病（IgG4-RD）成人患者。新闻稿指出，这是治疗这一患者群体的首个获批药物。此外，安进的在研减重疗法MariTide于2024年年末公布了积极的2期研究结果，已进入3期开发阶段。在没有2型糖尿病的肥胖或超重人群中，MariTide在第52周实现了平均体重减轻约20%，且未出现体重减轻平台期。武田2024年营收：约309亿美元2024年4月，美国FDA批准了武田的Entyvio皮下注射制剂，用于中度至重度活动性克罗恩病人患者在接受Entyvio静脉注射制剂诱导治疗后的维持治疗，进一步巩固了其在炎症性肠病领域的布局。FDA还批准了该公司的Eohilia（布地奈德口服混悬液）上市，治疗11岁以上嗜酸性粒细胞性食管炎（EoE）患者。新闻稿指出，这是FDA批准治疗EoE的首款口服疗法。近期，武田的在研多肽疗法rusfertide作为真性红细胞增多症（PV）标准治疗附加方案的3期研究达到主要终点，80%的患者不再需要接受放血治疗。2024年，田达成数起超10亿美元的战略合作和许可协议，囊获多款创新疗法的开发权益，包括Kumquat Biosciences公司的一种新型免疫调节癌症小分子抑制剂、AC Immune公司的阿尔茨海默病疗法ACI-24.060、用于肿瘤学、神经科学和炎症领域多个靶点的新型分子胶降解剂，以及血液疾病创新疗法elritercept。勃林格殷格翰2024年营收：约290亿美元近期，勃林格殷格翰为其用于治疗NSCLC的小分子药物zongertinib（BI 1810631）递交了新药申请（NDA），该疗法获得了优先审评资格，有望于今年获批。新闻稿指出，如果获批，zongertinib将成为针对携带HER2突变、既往接受过全身治疗的不可切除或转移性NSCLC成人患者的首个口服靶向疗法。该公司用于治疗渐进性肺纤维化（PPF）的小分子抑制剂nerandomilast已达3期临床试验终点，即将递交上市申请。2024年6月，勃林格殷格翰公布了其胰高血糖素/GLP-1受体双重激动剂survodutide（BI 456906）的积极2期临床试验结果，并即将开展针对MASH的3期临床试验。在这项2期研究中，多达64.5%的中晚期（F2和F3期）肝纤维化成人患者的肝纤维化得到改善，且MASH未恶化。2024年，勃林格殷格翰达成多起超5亿美元的收购和合作协议，包括针对MASH的RNAi疗法、针对精神分裂症的小分子疗法、用于治疗癌症的细胞周期蛋白抑制剂和创新蛋白酪氨酸磷酸酶N1和N2（PTPN1和PTPN2）小分子抑制剂。吉利德科学2024年营收：约286亿美元2024年8月，美国FDA加速批准了吉利德科学斥资43亿美元收购的小分子疗法Livdelzi与熊去氧胆酸（UDCA）联合用于治疗对UDCA应答不足的原发性胆汁性肝硬化（PBC）成人患者，或作为单药治疗对UDCA不耐受的患者，但不建议患有或发展为失代偿性肝硬化的患者使用Livdelzi。根据新闻稿，Livdelzi是在碱性磷酸酶（ALP）正常化、关键生物标志物和瘙痒控制方面，与安慰剂相比表现出统计学显著改善的首个疗法。2025年2月，该疗法获欧盟批准，用于相同的适应症。此外，该公司的突破性长效HIV疗法lenacapavir已获得FDA授予的优先审评资格，预计在今年6月19日之前完成审评。该疗法的上市申请在欧洲也获得了加速审评。Lenacapavir是一种“first-in-class”长效HIV病毒衣壳抑制剂，可以干扰HIV病毒衣壳蛋白的组装和拆卸，在病毒生命周期的多个阶段发挥作用。在两项3期临床试验中，近100%接受每半年一次lenacapavir注射的受试者没有出现HIV感染。拜耳2024年营收：约260亿美元2024年3月，拜耳达成了一项3.1亿美元的合作，获得了在欧洲商业化BridgeBio Pharma公司用于治疗伴有心肌病的转甲状腺素蛋白介导的淀粉样变性（ATTR-CM）的在研疗法acoramidis的独家许可。该疗法目前已在美国、欧洲和日本获批上市，用于治疗ATTR-CM。该公司超8亿美元收购的双重神经激肽-1，3（NK-1，3）受体拮抗剂elinzanetant达3期临床主要终点，公司已向FDA递交NDA，寻求批准elinzanetant用于治疗与更年期相关的中度至重度血管运动症状（VMS，也称为潮热）。德国默克2024年营收：约191亿美元德国默克过去一年通过与多家新锐公司达成合作和授权交易，扩展研发管线。2024年3月，该公司与C4 Therapeutics（C4T）公司签订一项许可和合作协议，合作开发针对C4T在其内部发现管线中推进的两个关键致癌蛋白靶点的靶向蛋白降解剂。2024年6月，德国默克与Biolojic Design公司达成多靶点药物发现合作。该合作将利用Biolojic Design的AI驱动发现平台来设计用于治疗癌症和免疫疾病的治疗性抗体。梯瓦2024年营收：约165亿美元近期，梯瓦公司公布了其与赛诺菲共同开发的在研TL1A靶向单抗duvakitug在2b期临床试验中获得的积极结果。结果显示，接受duvakitug治疗的两大炎症性肠病——溃疡性结肠炎和克罗恩病的患者在第14周时均获得显著缓解。两家公司预计在今年下半年启动3期临床试验。此外，该公司用于治疗精神分裂症的长效缓释皮下注射疗法TEV-‘749已达3期临床试验主要终点。这款疗法利用名为SteadyTeq的缓释技术，让活性药物olanzapine能够在每月一次给药的治疗方案下通过持续释放维持治疗剂量。在一项近期公布的患者和医疗保健专业人员态度和体验调查研究中，超过92%的患者对TEV-‘749的起始治疗方案、给药方案和药物本身感到满意或非常满意。CSL2024年营收：约152亿美元CSL所开发的基因疗法Hemgenix在2022年11月与2023年2月分别获美国FDA与欧盟批准，用于对中度至重度血友病B患者进行一次性治疗。这款疗法在2023年荣获有“医药界诺贝尔奖”之称盖伦奖的最佳孤儿药/罕见病产品奖。此外，欧盟委员会已于今年2月批准“first-in-class”疗法Andembry上市，用于预防12岁及以上成年和青少年患者的遗传性血管性水肿（HAE）发作。新闻稿指出，它是首款只需每月一针、靶向血浆蛋白因子XIIa的HAE发作预防疗法。美国FDA目前正在针对该疗法进行审评。参考资料：[1] The top 20 pharma companies by 2024 revenue. Retrieved April 21, 2025, from https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2024-revenue免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patient dosed in Phase 1/2 trial of IMC-R117C (PIWIL1) in colorectal and other gastrointestinal cancers Will present initial Phase 1 multiple ascending dose HIV data for IMC-M113V in 1Q 2025 and Phase 1 single ascending dose HBV data for IMC-I109V in 2H 2025 CTA/IND on track for IMC-S118AI (type 1 diabetes candidate) in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026 Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024 Conference call today, February 26 at 8:00 AM ET, 1:00 PM GMT (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 26 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. The Company has delivered 11 consecutive quarters of KIMMTRAK® (tebentafusp) revenue growth with continued penetration in the U.S. and launches in 14 new territories ex-U.S., while executing on the product’s lifecycle management program through two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications. The Company further advanced its clinical pipeline, enrolling patients in its three Phase 3 trials, initiating patient dosing in its Phase 1 trial with IMC-P115C, its half-life extended candidate targeting PRAME, and administering the first dose of the first PIWIL1-targeted immunotherapy for gastrointestinal cancers. Supported by a strong balance sheet, the Company also continued to innovate for sustainable growth, progressing two autoimmune candidates from its first-in-class, tissue-specific autoimmune platform towards clinical trial applications in 2025 and 2026. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and disciplined spending,” said Bahija Jallal, CEO of Immunocore. “As we enter 2025, we continue enrolling patients in our three Phase 3 melanoma trials, pursuing additional opportunities in our PRAME franchise, and developing the next generation of transformative immunomodulating therapies. We have line of sight to a significant amount of data over the next 12-18 months, starting with the HIV data this quarter.” “In 2024 we launched KIMMTRAK in 14 countries and delivered 30% year-on-year net sales growth resulting in 11 successive quarters of continuous growth since launch,” said Ralph Torbay, Head of Commercial. “In 2025, we expect incremental growth in metastatic uveal melanoma driven by further expansion into the U.S. community and additional launches. We will also continue to enroll patients in the Phase 3 TEBE-AM trial for advanced cutaneous melanoma, with data expected in 2026, and the Phase 3 ATOM trial for adjuvant uveal melanoma.“ Full Year and Fourth Quarter 2024 Highlights (including post-period) Financial Results Total net product revenue (or ‘net sales’) arising from the sales of KIMMTRAK (tebentafusp) was $84.1 million in the fourth quarter of 2024, of which $63.8 million was generated in the United States, $17.8 million in Europe and $2.5 million in international regions. For the year ended December 31, 2024, the Company generated net sales of KIMMTRAK in the amount of $310.0 million, of which $226.7 million was in the United States, $73.2 million in Europe and $10.1 million in international regions. Research & development (R&D) expenses for the year 2024 were $222.2 million, compared to $163.5 million for the year 2023. Selling, general and administrative (SG&A) expenses for the year 2024 were $155.8 million, compared to $144.5 million for the year 2023. Net loss for the fourth quarter of 2024 was $23.8 million compared to a net loss of $19.7 million in the same period in 2023, and full year net loss for 2024 was $51.1 million compared to a full year net loss of $55.3 million in 2023. The fourth quarter basic and diluted loss per share was $0.47 compared to $0.40 for the fourth quarter of 2023. Basic and diluted loss per share for the year 2024 was $1.02, compared to $1.13 for the year 2023. Cash, cash equivalents and marketable securities at December 31, 2024, were $820.4 million. In November 2024, the Company repaid in full its existing Pharmakon loan of $50.0 million. KIMMTRAK The Company’s lead product, KIMMTRAK® (tebentafusp), is approved in 39 countries and has been launched in 24 countries to date for HLA-A*02:01+ people with metastatic uveal melanoma (mUM). KIMMTRAK continues to be the standard of care in most markets where it is launched. The Company sees three key growth areas for KIMMTRAK, including continued global expansion in mUM, the potential expansion into 2L+ advanced cutaneous melanoma (CM), and the potential expansion into adjuvant uveal melanoma. Metastatic uveal melanoma In 2024, KIMMTRAK was launched in 14 additional countries (including Australia, Spain, Poland, and the United Kingdom, excluding Scotland) for a total of 24 countries launched at the end of 2024. The Company plans to expand access to KIMMTRAK through market share growth in key areas, early patient identification, and additional launches globally. Second-line and later cutaneous melanoma The Company is currently enrolling the TEBE-AM registrational Phase 3 trial and expects to complete enrollment in the first half of 2026. The Phase 3 is enrolling three arms: tebentafusp monotherapy, tebentafusp in combination with pembrolizumab, and a control (investigator's choice of therapy including options such as investigator’s choice of clinical trials, chemotherapy, or retreatment with anti-PD1 or BRAF therapy). There is great unmet need in second and later-line cutaneous melanoma, with no therapy having shown an Overall Survival (OS) improvement post checkpoint inhibitors in a randomized clinical trial. The Company estimates that there is a potential to address up to 4,000 previously treated advanced CM patients. Adjuvant uveal (or ocular) melanoma In December 2024, the first patient was randomized in the Phase 3 Adjuvant Trial in Ocular Melanoma (ATOM), led by the European Organisation for Research and Treatment of Cancer (EORTC). The Company estimates that the HLA-A*02:01 high risk adjuvant uveal melanoma patient population could be up to 1,200 patients. PRAME portfolio Brenetafusp is the Company’s lead PRAME-A02 ImmTAC bispecific candidate. Brenetafusp is being evaluated in combination with nivolumab in a Phase 3 registrational trial (PRISM-MEL-301) in patients with first-line advanced cutaneous melanoma, and in a Phase 1/2 clinical trial as monotherapy and in combination across multiple tumor types, including ovarian cancer and non-small cell lung cancer (NSCLC). PRISM-MEL-301 – First PRAME Phase 3 clinical trial with brenetafusp in first-line advanced cutaneous melanoma The Company randomized the first patient in the registrational Phase 3 clinical trial evaluating brenetafusp + nivolumab versus a control arm of either nivolumab or nivolumab + relatlimab for HLA-A*02:01 patients with first-line, advanced or metastatic cutaneous melanoma. Selection of the go-forward dose by the independent data monitoring committee is expected in the second half of 2025. Despite approved therapies, there remains a need for improved progression free survival and overall survival, and there is the potential to address an estimated 10,000 patients. Phase 1/2 clinical trial of brenetafusp in multiple solid tumors In 2024, the Company presented clinical data for the ongoing Phase 1/2 trial evaluating brenetafusp, as a monotherapy and in combination with standard of care. Brenetafusp monotherapy showed clinical activity (disease control rate, partial responses, and stable disease) and ctDNA molecular responses in late-line cutaneous melanoma (at ASCO 2024) and platinum-resistant, high grade serous ovarian cancer (at ESMO 2024). Brenetafusp was safely combined with anti-PD1 and all tested chemotherapies in the trial. The Company continues to evaluate brenetafusp in a Phase 1/2 trial in combination with non-platinum chemotherapies in platinum-resistant ovarian cancer (PROC) and with bevacizumab or with platinum chemotherapy in earlier lines of platinum-sensitive ovarian cancer (PSOC). In the same trial, the Company continues signal detection in metastatic non-small cell lung cancer cohorts, including brenetafusp in combination with docetaxel and with osimertinib in earlier-line NSCLC. The Company estimates that, across all solid tumors, the annual number of patients worldwide who test positive for HLA-A*02:01 and can potentially benefit from this program is up to 150,000. IMC-P115C (PRAME HLA-A02 Half-Life Extended) & IMC-T119C (PRAME HLA-A24) In December 2024, the first dose was administered to a patient in the Phase 1 dose escalation trial, in multiple solid tumors, with IMC-P115C. IMC-P115C is the Company’s first half-life extended ImmTAC therapy – targeting the same PRAME peptide and with the same CD3 effector and TCR specificity as brenetafusp. It is designed to improve patient convenience by reducing the frequency of treatment administration. The Company submitted a clinical trial application (CTA) to regulatory authorities for IMC-T119C (targeting PRAME HLA-A24), in December 2024. IMC-R117C (PIWIL1) for colorectal and other gastrointestinal cancers In December 2024, the first patient was dosed with IMC-R117C (targeting PIWIL1) in the Phase 1/2 dose escalation trial. PIWIL1 is believed to play a role in tumor progression and is expressed across a range of tumors, including colorectal cancer. The trial evaluates IMC-R117C in HLA-A*02:01-positive patients with advanced solid tumors, including colorectal cancer, as a single agent and in combination with standards of care. Enrolling ImmTAV candidates for a functional cure in infectious diseases The Company’s bispecific TCR technology platform has potential to offer a new approach for the treatment of chronic infections and aims to eliminate evidence of remaining virus in circulation after a person stops taking medication - known as a ‘functional cure’. Two investigational candidates are in Phase 1 clinical trials for people living with human immunodeficiency virus (HIV) and people with chronic hepatitis B infection (HBV). Phase 1 trial of IMC-M113V (Gag-A02) for people living with HIV The Company continues to enroll people living with HIV (PLWH) in the multiple ascending dose (MAD) part of the Phase 1 clinical trial with IMC-M113V and will present data from the initial three cohorts during the first quarter of 2025. The trial aims to identify a safe and tolerable dosing schedule, test whether IMC-M113V could lead to reduction in the viral reservoir and, after stopping all therapies (antiretroviral therapies and IMC-M113V), delay or prevent HIV rebound (known as functional cure). A biologically active dose has been reached, and the Company is enrolling more PLWH to further characterize anti-viral activity and explore higher doses. Phase 1 trial of IMC-I109V (Envelope-A02) for people living with HBV The Company completed the single ascending dose (SAD) portion of the Phase 1 trial with IMC-I109V for people living with hepatitis B virus (HBV) and plans to present this data in the second half of 2025. Tissue-specific down modulation of the immune system for autoimmune diseases The key differentiator of the ImmTAAI platform is tissue-specific, down modulation of the immune system, as the candidates suppress pathogenic T cells via PD1 receptor agonism only when tethered to the target tissue. IMC-S118AI for type 1 diabetes The Company plans to file a CTA or investigational new drug application (IND) for IMC-S118AI (PPI x PD1) in the second half of 2025. IMC-S118AI is targeted specifically to the pancreatic beta-cell and intended as a disease-modifying treatment in type 1 diabetes. IMC-S118AI recognizes a peptide from pre-pro-insulin protein that is presented by HLA-A02 on beta cells and has a PD1 agonist effector arm. IMC-U120AI initially for atopic dermatitis - first universal program IMC-U120AI (CD1a x PD1) is a CD1a-tethered PD1 agonist ImmTAAI therapy. It is Immunocore’s first non-HLA-restricted program (i.e. universal for all populations). The Company plans to file a CTA/IND for IMC-U120AI in 2026, initially for a Phase 1 dose escalation trial in atopic dermatitis. CD1a is an HLA-like protein that is expressed on skin and mucosal antigen presenting cells, such as Langerhans cells. Both CD1a and Langerhans cells play an important role in triggering allergic inflammation in atopic dermatitis and potentially other immune diseases. IMC-U120AI has a dual mechanism of action in that it will block CD1a (which presents lipids) from activating CD1a-specific T cells and will prevent HLA Class I/II (which presents peptides) from activating T cells via PD1 agonism on the T cell. Corporate update In February, Dr. William Pao was appointed as a non-executive member of the Company’s Board of Directors. William is the co-founder and Chief Executive Officer of Revelio Therapeutics, Inc. Prior to Revelio, Dr. Pao held executive leadership positions in early- and late-stage R&D at F. Hoffmann-La Roche AG and Pfizer respectively. He is a member of the American Association for Cancer Research’s board of directors. Financial Results Basic and diluted loss per share was $0.47 and $1.02 for the quarter and year ended December 31, 2024, respectively, as compared to a basic and diluted loss per share of $0.40 and $1.13, respectively, for the same periods in 2023. Net loss for the quarter and year ended December 31, 2024, was $23.8 million and $51.1 million, respectively, as compared to $19.7 million and $55.3 million, respectively, for the same periods in 2023. For the fourth quarter and year ended December 31, 2024, the Company generated net sales of $84.1 million and $310.0 million, respectively, arising from the sale of KIMMTRAK, of which $63.8 million and $226.7 million, respectively was in the United States, $17.8 million and $73.2 million, respectively, was in Europe, and $2.5 million and $10.1 million, respectively, was in the international regions. The increase in net sales was due primarily to increased volume in the United States and global country expansion, as the Company continues its commercialization efforts. For the fourth quarter and year ended December 31, 2024, Immunocore’s R&D expenses were $60.9 million and $222.2 million, respectively as compared to $45.6 million and $163.5 million for the quarter and year ended December 31, 2023. These increases were primarily driven by expenses incurred for the Company’s PRAME programs as a result of the initiation of our registrational Phase 3 PRISM-MEL-301 clinical trial, scale-up of manufacturing and an increase in the number of patients in combination expansions in the brenetafusp Phase 1/2 clinical trial. R&D expenses incurred for the tebentafusp programs also increased due to the TEBE-AM and ATOM Phase 3 clinical trials. The Company expects R&D expenses to increase in 2025 as the Company further advances clinical and preclinical pipeline candidates. For the quarter and year ended December 31, 2024, the Company’s SG&A expenses were $42.3 million and $155.8 million, respectively, compared to $41.4 million and $144.5 million for the quarter and year ended December 31, 2023. These increases were primarily related to increases in the number of employees engaged in business support functions to support our growing pipeline and global commercial expansion, and in investments in patient support initiatives, information technology and facilities costs. The Company expects SG&A expenses to be mostly consistent with Q4 2024 expense levels over the course of 2025. Cash, cash equivalents and marketable securities at December 31, 2024, were $820.4 million. In November 2024, the Company repaid in full its existing Pharmakon loan of $50.0 million. See the Company’s Annual Report on Form 10-K filed today with the SEC for more information. Audio Webcast Immunocore will host a conference call today, February 26, 2025, at 8:00 A.M. ET / 1:00 PM GMT, to discuss the fourth quarter and full year 2024 financial results and provide a business update. The call will also be available via webcast by visiting the Events & Presentations section on Immunocore’s website. A replay of this webcast will be available for 30 days. Conference Call Details: Domestic (toll-free): 877-405-1239 International (toll): +1 201-389-0851 Upcoming Investor Conferences B. Riley Securities Precision Oncology & Radiopharma Conference Friday, February 28, 2025, at 10:00 a.m. ET ## About ImmTAC® molecules for cancer Immunocore’s proprietary T cell receptor (TCR) technology generates a novel class of bispecific biologics called ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) molecules that are designed to redirect the immune system to recognize and kill cancerous cells. ImmTAC molecules are soluble TCRs engineered to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune-activating effector function. Based on the demonstrated mechanism of T cell infiltration into human tumors, the ImmTAC mechanism of action holds the potential to treat hematologic and solid tumors, regardless of mutational burden or immune infiltration, including immune “cold” low mutation rate tumors. About ImmTAV® molecules for infectious diseases ImmTAV (Immune mobilizing monoclonal TCRs Against Virus) molecules are novel bispecifics that are designed to enable the immune system to recognize and eliminate virally infected cells. Immunocore is advancing clinical candidates to achieve functional cure for patients with HIV and hepatitis B virus (HBV). The Company aims to achieve sustained control of HIV after patients stop anti-retroviral therapy (ART), without the risk of virological relapse or onward transmission. This is known as ‘functional cure’. For the treatment of HBV, the Company aims to achieve sustained loss of circulating viral antigens and markers of viral replication after stopping medication for people living with chronic HBV. About ImmTAAITM molecules for autoimmune diseases ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune diseases, including type 1 diabetes and inflammatory dermatological diseases. About PRISM-MEL-301 (NCT06112314) – Phase 3 trial with brenetafusp (IMC-F106C, PRAME-A02) in 1L advanced cutaneous melanoma The Phase 3 registrational trial is randomizing HLA-A*02:01-positive patients with previously untreated advanced melanoma, to brenetafusp + nivolumab versus nivolumab or nivolumab + relatlimab, depending on the country where the patient is enrolled. The trial will initially randomize to three arms: two brenetafusp dose regimens (40 mcg and 160 mcg) and a control arm. One of the two brenetafusp dose regimens will be discontinued after an initial review of the first 60 patients randomized to the two experimental arms (90 patients randomized total). The primary endpoint of the trial is progression free survival (PFS) by blinded independent central review (BICR), with secondary endpoints of overall survival (OS) and overall response rate (ORR). About the IMC-F106C-101 Phase 1/2 trial IMC-F106C-101 is a first-in-human, Phase 1/2 trial in patients with multiple solid tumors, including non-small cell lung and ovarian cancers. The Phase 1 dose escalation trial was designed to determine the maximum tolerated dose (MTD), as well as to evaluate the safety, preliminary anti-tumor activity and pharmacokinetics of IMC-F106C (brenetafusp), a bispecific protein built on Immunocore’s ImmTAC technology, and the Company’s first molecule to target the PRAME antigen. The Company is currently focusing on enrolling patients in combination arms with standards-of-care across multiple tumor types. About TEBE-AM – Phase 3 registrational trial with tebentafusp in previously treated advanced cutaneous melanoma The trial is randomizing patients with second-line or later advanced cutaneous melanoma who have progressed on an anti-PD1, received prior ipilimumab and, if applicable, received a BRAF kinase inhibitor. Patients are randomized to one of three arms, including tebentafusp – as monotherapy or in combination with an anti-PD1 – or a control arm. The primary endpoint is overall survival. About the ATOM Phase 3 trial The EORTC-led Phase 3 clinical trial will include sites in 10 EU countries and the United States and will randomize HLA-A*02:01-positive patients with high-risk primary uveal melanoma after definitive treatment, by surgery or radiotherapy, and no evidence of metastatic disease on imaging. The trial is expected to enroll a total of 290 patients who will be randomized 1:1 to one of two arms: tebentafusp as monotherapy or observation. The primary endpoint of the trial is relapse-free survival (RFS), with secondary objectives of overall survival and safety and tolerability of tebentafusp. Exploratory objectives include comparison of health-related quality of life between the treatment arms and evaluation of the role of circulating tumor DNA (ctDNA) as a biomarker for the presence of residual disease. About Uveal Melanoma Uveal melanoma is a rare and aggressive form of melanoma affecting the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare, and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK. About Cutaneous Melanoma Cutaneous melanoma (CM) is the most common form of melanoma. It is the most aggressive skin carcinoma and is associated with the vast majority of skin cancer-related mortality. The majority of patients with CM are diagnosed before metastasis but survival remains poor for the large proportion of patients with metastatic disease. Despite recent progress in advanced melanoma therapy, there is still an unmet need for new therapies that improve first-line response rates and duration of response as well as for patients who are refractory to first-line treatments. About KIMMTRAK® KIMMTRAK is a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. This is the first molecule developed using Immunocore’s ImmTAC technology platform, designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom. IMPORTANT SAFETY INFORMATION Cytokine Release Syndrome (CRS), which may be serious or life-threatening, occurred in patients receiving KIMMTRAK. Monitor for at least 16 hours following first three infusions and then as clinically indicated. Manifestations of CRS may include fever, hypotension, hypoxia, chills, nausea, vomiting, rash, elevated transaminases, fatigue, and headache. CRS occurred in 89% of patients who received KIMMTRAK, with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients are euvolemic prior to initiating the infusions. Closely monitor patients for signs or symptoms of CRS following infusions of KIMMTRAK. Monitor fluid status, vital signs, and oxygenation level and provide appropriate therapy. Withhold or discontinue KIMMTRAK depending on persistence and severity of CRS. Skin Reactions Skin reactions, including rash, pruritus, and cutaneous edema occurred in 91% of patients treated with KIMMTRAK. Monitor patients for skin reactions. If skin reactions occur, treat with antihistamine and topical or systemic steroids based on persistence and severity of symptoms. Withhold or permanently discontinue KIMMTRAK depending on the severity of skin reactions. Elevated Liver Enzymes Elevations in liver enzymes occurred in 65% of patients treated with KIMMTRAK. Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total blood bilirubin prior to the start of and during treatment with KIMMTRAK. Withhold KIMMTRAK according to severity. Embryo-Fetal Toxicity KIMMTRAK may cause fetal harm. Advise pregnant patients of potential risk to the fetus and patients of reproductive potential to use effective contraception during treatment with KIMMTRAK and 1 week after the last dose. The most common adverse reactions (≥30%) in patients who received KIMMTRAK were cytokine release syndrome, rash, pyrexia, pruritus, fatigue, nausea, chills, abdominal pain, edema, hypotension, dry skin, headache, and vomiting. The most common (≥50%) laboratory abnormalities were decreased lymphocyte count, increased creatinine, increased glucose, increased AST, increased ALT, decreased hemoglobin, and decreased phosphate. For more information, please see full Summary of Product Characteristics (SmPC) or full U.S. Prescribing Information (including BOXED WARNING for CRS). About KIMMTRAKConnect Immunocore is committed to helping patients who need KIMMTRAK obtain access via our KIMMTRAKConnect program. The program provides services with dedicated nurse case managers who provide personalized support, including educational resources, financial assistance, and site of care coordination. To learn more, visit KIMMTRAKConnect.com or call 844-775-2273. About Immunocore Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs​ in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom. Forward Looking Statements This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “aim”, “continue”, “target” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the potential of the Company’s melanoma franchise, the Company’s ability to advance its clinical pipeline and to innovate for sustainable growth; the key growth areas for the KIMMTRAK opportunity, including continued global expansion in mUM, the potential expansion into adjuvant uveal melanoma, and 2L+ advanced cutaneous melanoma; the commercial performance of KIMMTRAK; the potential benefits and advantages that KIMMTRAK will provide for patients; expectations regarding the estimated size of the patient populations for the Company’s product candidates; expectations regarding the design, progress, timing, enrollment, randomization, scope, expansion, funding, and results of the Company’s existing and planned clinical trials , those of the Company’s collaboration partners or the combined clinical trials with the Company’s collaboration partners; the timing and sufficiency of clinical trial outcomes to support potential approval of any of the Company’s product candidates or those of, or combined with, its collaboration partners; the Company’s goals to develop and commercialize product candidates based on its KIMMTRAK platform alone or with collaboration partners; the expected submission of clinical trial applications; and the potential regulatory approval, expected clinical benefits and availability of the Company’s product candidates. Any forward-looking statements are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially and adversely from those set forth in or implied by such forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of worsening macroeconomic conditions on the Company’s business, financial position, strategy and anticipated milestones, including Immunocore’s ability to conduct ongoing and planned clinical trials; Immunocore’s ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products; Immunocore’s ability to obtain and maintain regulatory approval of its product candidates, including KIMMTRAK; Immunocore’s ability and plans in continuing to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK and any future approved products; Immunocore’s ability to successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market opportunities; unexpected safety or efficacy data observed during preclinical studies or clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s need for and ability to obtain additional funding, on favorable terms or at all, including as a result of worsening macroeconomic conditions, including changes in inflation and interest rates and unfavorable general market conditions, and the impacts thereon of the war in Ukraine, the conflict in the Middle East, and global geopolitical tension; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any of its product candidates it or its collaborators are developing; and the success of Immunocore’s current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section titled "Risk Factors" in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 26, 2025, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information, except as required by law. Contact Information Immunocore Sébastien Desprez, Head of Communications T: +44 (0) 7458030732 E: sebastien.desprez@immunocore.com Follow Immunocore on LinkedIn: @Immunocore Investor Relations Clayton Robertson / Morgan Warenius T: +1 (215) 384-4781 E: ir@immunocore.com Released February 26, 2025